Regarding the U.S. sales partnership for Bondlido, the sales license agreement is expected to be concluded in October 2026, and the launch timing has been revised to the fourth quarter of 2026. The revenue scale is unknown, but market size is estimated at approx. 44 billion yen. Preparations are underway due to revisions in contract terms. The impact on the fiscal year ending December 2026 is expected to be minor.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4586","jir_company_name":"MedRx Co., Ltd","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-09-30","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/4586-20260930-01.pdf","jir_short_summary":"Regarding the U.S. sales partnership for Bondlido, the sales license agreement is expected to be concluded in October 2026, and the launch timing has been revised to the fourth quarter of 2026. The revenue scale is unknown, but market size is estimated at approx. 44 billion yen. Preparations are underway due to revisions in contract terms. The impact on the fiscal year ending December 2026 is expected to be minor.","jir_summary":"### Partnership Details and Contract Progress\nMedRx is advancing a sales partnership with Terrain Pharmaceuticals for Bondlido in the U.S. market and is finalizing the term sheet toward concluding a sales license agreement. Given the product's competitive attributes in the market (low skin irritation, adhesion strength, retention during movement), the company is reviewing sales strategy and supply plans. Although adjustments to contract terms have required time, the agreement is expected to be signed in October while launch preparations proceed in parallel.\n\n### Impact on Performance and Market Opportunity\nThe U.S. market for Bondlido is large and the product could be a superior alternative to Lidoderm. Terrain has a nationwide distribution network and a track record with topical analgesics, so future sales performance could exceed expectations depending on partnership terms. However, the effect on the fiscal year ending December 2026 is expected to be minor.","jir_financial_highlights":"Estimated Bondlido market size: approx. 44 hundred million yen (Unknown)\nTiming of sales license agreement conclusion: Expected October 2026 (Revised (initially expected September \u2192 October))\nLaunch timing: Expected Q4 2026 (No change)\nImpact on fiscal year ending December 2026: Minor (Unknown)","jir_category":"","jir_hashtags":"#MedRx, #Partnership, #Bondlido","jir_key_figures":"Estimated Bondlido market size: approx. 44 hundred million yen\nTiming of sales license agreement conclusion: Expected October 2026\nLaunch timing: Expected Q4 2026","jir_meta_title":"MedRx Co., Ltd: Negotiating U.S. Sales Partnership for Bondlido with Terrain | Launch Expected Q4 2026","jir_meta_description":"MedRx is progressing discussions with U.S. Terrain Pharmaceuticals for a Bondlido sales partnership. Agreement expected in October, targeting a Q4 2026 launch. Market size is estimated at approx. 44 hundred million yen and the impact on fiscal 2026 is expected to be minor.","jir_og_title":"U.S. Sales Partnership for Bondlido; Launch Expected Q4 2026","jir_og_description":"MedRx is negotiating U.S. rollout of Bondlido with Terrain. Agreement expected in October and launch planned for Q4 2026. Market size estimated at approx. 44 hundred million yen.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59495,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"m_and_a_alliance","footnotes":""},"sector":[],"importance":[],"class_list":["post-125032","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n